Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KLX-01 is an investigational small molecule ketone ester developed by KetoLipix Therapeutics. It is designed as an active pharmaceutical ingredient (API) to induce exogenous metabolic ketosis, providing a rapid and controlled elevation of blood ketone levels, specifically beta-hydroxybutyrate (BHB). By serving as an alternative energy substrate to glucose, KLX-01 aims to address metabolic deficiencies in various tissues. The therapeutic focus of KetoLipix includes conditions such as heart failure and neurodegenerative disorders, where enhancing cellular energetics through ketosis may provide clinical benefit. Unlike dietary ketone supplements, KLX-01 is being developed under pharmaceutical standards for specific medical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KLX-01.